<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02298179</url>
  </required_header>
  <id_info>
    <org_study_id>205219</org_study_id>
    <secondary_id>2014-000145-69</secondary_id>
    <secondary_id>V122_01</secondary_id>
    <nct_id>NCT02298179</nct_id>
  </id_info>
  <brief_title>To Evaluate the Safety and Ability of the Medicine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults</brief_title>
  <official_title>A Phase 1 Randomized, Observer Blind, Placebo Controlled, Dosage-Escalation Single Center Study to Evaluate the Safety and Immunogenicity of an RSV Fusion Glycoprotein (F) Subunit Vaccine in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and immunogenicity of two doses of the
      investigational RSV F subunit vaccine administered intramuscularly (IM). In this current
      Phase 1, first-in-human study, the three different antigen amounts that have been selected
      will be evaluated in a stepwise manner in three different cohorts (cohort 1: low dosage of
      RSV F subunit vaccine, cohort 2: middle dosage of RSV F subunit vaccine, and cohort 3: high
      dosage of RSV F subunit vaccine). In addition, the effect of an adjuvant, either aluminum
      hydroxide or MF59, and antibody kinetics post-vaccination at different time points will be
      evaluated as compared to unadjuvanted RSV F subunit vaccine at the same dosage levels
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2014</start_date>
  <completion_date type="Actual">March 27, 2017</completion_date>
  <primary_completion_date type="Actual">March 27, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage and frequency of subjects with solicited local/systemic adverse events up to 7 days after vaccination</measure>
    <time_frame>7 days post-vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage and frequency of subjects with unsolicited adverse events for 28 days after vaccination</measure>
    <time_frame>28 days post-vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage and frequency of subjects with SAEs, NOCDs, AESIs, and other unsolicited AEs for 1 year after vaccination</measure>
    <time_frame>365 days post-vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GMTs, and proportion of subjects with at least a 4-fold increase in serum anti-RSV NAb titer after vaccination</measure>
    <time_frame>28 days post-vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GMTs, and proportion of subjects with at least a 4-fold increase in serum anti-RSV NAb titer after each vaccination</measure>
    <time_frame>28 days and 6 months post-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs, and proportion of subjects with at least a 4-fold increase in serum total binding Ab to RSV F, G, and N proteins after each vaccination</measure>
    <time_frame>28 days post each vaccination, 6 months post-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of serum NAb titer to serum total binding Ab titer to RSV proteins F, G, and N at Day 1, Day 29, Day 57, and Day 181</measure>
    <time_frame>28 days post each vaccination, 6 months post-vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">288</enrollment>
  <condition>Respiratory Syncytial Virus (RSV)</condition>
  <arm_group>
    <arm_group_label>1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RSV F subunit vaccine with no adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RSV F subunit vaccine with aluminum hydroxide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RSV F subunit vaccine with MF59</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RSV F subunit vaccine with no adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RSV F subunit vaccine with aluminum hydroxide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RSV F subunit vaccine with MF59</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RSV F subunit vaccine with no adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RSV F subunit vaccine with aluminum hydroxide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RSV F subunit vaccine with MF59</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RSV F subunit vaccine-Low dosage; no adjuvant</intervention_name>
    <description>Low dosage; no adjuvant</description>
    <arm_group_label>1A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RSV F subunit vaccine-Medium dosage; no adjuvant</intervention_name>
    <description>Medium dosage; no adjuvant</description>
    <arm_group_label>1B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RSV F subunit vaccine-High dosage; no adjuvant</intervention_name>
    <description>High dosage; no adjuvant</description>
    <arm_group_label>1C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RSV F subunit vaccine-Low dosage; with aluminum hydroxide</intervention_name>
    <description>Low dosage; with aluminum hydroxide</description>
    <arm_group_label>2A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RSV F subunit vaccine-Medium dosage; with aluminum hydroxide</intervention_name>
    <description>Medium dosage; with aluminum hydroxide</description>
    <arm_group_label>2B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RSV F subunit vaccine-High dosage; with aluminum hydroxide</intervention_name>
    <description>High dosage; with aluminum hydroxide</description>
    <arm_group_label>2C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RSV F subunit vaccine-Low dosage; with MF59</intervention_name>
    <description>Low dosage; with MF59</description>
    <arm_group_label>3A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RSV F subunit vaccine-Medium dosage; with MF59</intervention_name>
    <description>Medium dosage; with MF59</description>
    <arm_group_label>3B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RSV F subunit vaccine-High dosage; with MF59</intervention_name>
    <description>High dosage; with MF59</description>
    <arm_group_label>3C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo-Sterile Saline</intervention_name>
    <description>Sterile Saline</description>
    <arm_group_label>1D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo-Sterile Saline</intervention_name>
    <description>Sterile Saline</description>
    <arm_group_label>2D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo-Sterile Saline</intervention_name>
    <description>Sterile Saline</description>
    <arm_group_label>3D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and non-pregnant females 18 to 45 years of age at time of enrollment.

        Exclusion Criteria:

          1. Individuals with any severe chronic or acute disease.

          2. Individuals with a history of illness or with an ongoing illness that may pose
             additional risk to the subject if he/she participates in the study, including the
             following:

               -  History of any chronic respiratory illness, including current diagnosis of asthma
                  within 2 years, exercise induced wheezing, reactive airway disease, emphysema,
                  chronic bronchitis, cystic fibrosis or chronic obstructive pulmonary disease
                  (COPD).

               -  Any respiratory illness within 7 days prior to receiving the first study
                  vaccination.

               -  Any active pulmonary infection or other inflammatory conditions, even in the
                  absence of febrile episodes, within 14 days prior to the first study vaccination.

               -  Hepatitis B or hepatitis C infection.

          3. Individuals participating in any clinical trial with another investigational product
             28 days prior to receiving the first study vaccination or intent to participate in
             another clinical study at any time during the conduct of this study.

          4. Individuals who have received any vaccine 28 days prior to enrollment in this study,
             or who plan to receive any non-study vaccines within 28 days of the second dose of
             study vaccine.

          5. If female, 'of childbearing potential', sexually active and has not used any of the
             'acceptable contraceptive methods' for at least two months prior to study entry.

          6. If female subject of childbearing potential and have a positive urine pregnancy test
             prior to study injections, or are currently lactating.

          7. If female of childbearing potential and sexually active, refusal to use an 'acceptable
             contraceptive method' through to three weeks after last study vaccination.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2014</study_first_submitted>
  <study_first_submitted_qc>November 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2014</study_first_posted>
  <last_update_submitted>June 29, 2017</last_update_submitted>
  <last_update_submitted_qc>June 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>MF59 oil emulsion</mesh_term>
    <mesh_term>Aluminum Hydroxide</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 26, 2018</submitted>
    <submission_canceled>May 17, 2018</submission_canceled>
    <submitted>May 17, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

